Alanine 6.6 mg/mL - search results

paracetamol/ibuprofen vale 32 mg/ml + 9.6 mg/ml oral suspension

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - oral suspension - ibuprofen 9.6 mg paracetamol 32 mg - analgesics

Malta - English - Medicines Authority

paracetamol/ibuprofen suspension vale 32 mg/ml + 9.6 mg/ml oral suspension

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - oral suspension - ibuprofen 9.6 mg paracetamol 32 mg - analgesics

Malta - English - Medicines Authority

paraibucomb 32 mg/ml + 9.6 mg/ml oral suspension

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - oral suspension - paracetamol 32 mg ibuprofen 9,6 mg - analgesics

Malta - English - Medicines Authority

paracetamol/ibuprofen vale 32 mg/ml + 9.6 mg/ml oral suspension

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - oral suspension - paracetamol 32 mg ibuprofen 9.6 mg - analgesics

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

periolimel n4e inf. emuls. i.v.

baxter sa-nv - sodium acetate trihydrate 1,16 g/l; sodium glycerophosphate hydrate - eq. sodium glycerophosphate 1,91 mg/ml; glycine 1,76 mg/ml; glutamic acid 1,26 mg/ml; valine 1,62 mg/ml; arginine 2,53 mg/ml; leucine 1,76 mg/ml; potassium chloride 1,19 mg/ml; magnesium chloride hexahydrate 0,45 mg/ml; serine 1 mg/ml; proline 1,51 mg/ml; alanine 3,66 mg/ml; lysine acetate 2,81 g/l - eq. lysine 1,99 mg/ml; histidine 1,51 mg/ml; threonine 1,26 mg/ml; tryptophan 0,42 mg/ml; soyabean oil + olive oil 30 mg/ml; aspartic acid 0,73 mg/ml; glucose monohydrate 82,5 mg/ml - eq. glucose anhydrous 75 g/l; calcium chloride dihydrate 0,3 g/l; tyrosine 0,06 mg/ml; isoleucine 1,26 mg/ml; methionine 1,26 mg/ml; phenylalanine 1,76 mg/ml - emulsion for infusion - methionine 1.26 mg/ml; proline 1.51 mg/ml; lysine acetate; valine 1.62 mg/ml; threonine 1.26 mg/ml; calcium chloride dihydrate; glycine 1.76 mg/ml; tryptophan 0.42 mg/ml; leucine 1.76 mg/ml; serine 1 mg/ml; sodium glycerophosphate hydrate; glutamic acid 1.26 mg/ml; magnesium chloride hexahydrate 0.45 mg/ml; tyrosine 0.06 mg/ml; isoleucine 1.26 mg/ml; arginine 2.53 mg/ml; glucose monohydrate 82.5 mg/ml; aspartic acid 0.73 mg/ml; soyabean oil + olive oil 30 mg/ml; alanine 3.66 mg/ml; phenylalanine 1.76 mg/ml; potassium chloride 1.19 mg/ml; sodium acetate trihydrate; histidine 1.51 mg/ml - combinations

New Zealand - English - Medsafe (Medicines Safety Authority)

aminosyn rf

intermed medical ltd - arginine 6 mg/ml; histidine 4.29 mg/ml; isoleucine 4.62 mg/ml; leucine 7.26 mg/ml; lysine 5.35 mg/ml; methionine 7.26 mg/ml; phenylalanine 7.26 mg/ml; threonine 3.3 mg/ml; tryptophan 1.65 mg/ml; valine 5.28 mg/ml - solution for infusion - 5.2 % - active: arginine 6 mg/ml histidine 4.29 mg/ml isoleucine 4.62 mg/ml leucine 7.26 mg/ml lysine 5.35 mg/ml methionine 7.26 mg/ml phenylalanine 7.26 mg/ml threonine 3.3 mg/ml tryptophan 1.65 mg/ml valine 5.28 mg/ml excipient: acetic acid hydrochloric acid nitrogen sodium metabisulfite water for injection

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smofkabiven peripheral 14mg/ml+12mg/ml+11mg/ml+3mg/ml+5mg/ml+7,4mg/ml+6,6mg/ml+4,3mg/ml+5,1mg/ml+11,2mg/ml+6,5mg/ml+1mg/ml+4,4mg

fresenius kabi ab - camera i- l-alanine, l-arginine, glycine, l-histidine, l-isoleucine, l-leucine, l-lysine (lysine acetate), l-methionine, l-phenylalanine, l-proline, l-serine, taurine, l-threonine, l-triyptophan, l-tyrosine, l-valine, calcium chloride(calcium chloride dihydrate), sodium glycerophosphate (sodium glycerophosphate hydrate), magnesium sulfate (magnesium sulfate heptahydrate), potassium chloride, sodium acetate (sodium acetate trihydrate), zinc sulfate (zinc sulfate heptahydrate), camera ii-glucose (glucose mono - emulsion for infusion - 14mg/ml+12mg/ml+11mg/ml+3mg/ml+5mg/ml+7,4mg/ml+6,6mg/ml+4,3mg/ml+5,1mg/ml+11,2mg/ml+6,5mg/ml+1mg/ml+4,4mg/ml+2mg/ml+0,4mg/ml+6,2

smofkabiven central 14mg/ml+12mg/ml+11mg/ml+3mg/ml+5mg/ml+7,4mg/ml+6,6mg/ml+4,3mg/ml+5,1mg/ml+11,2mg/ml+6,5mg/ml+1mg/ml+4,4mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

vitrakvi larotrectinib (as sulfate) 20 mg/ml bottle

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; hydroxypropylbetadex; purified water; flavour; sorbitol; methyl hydroxybenzoate; citric acid; sucrose; glycerol; monobasic sodium phosphate; potassium sorbate - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Australia - English - Department of Health (Therapeutic Goods Administration)

vitrakvi larotrectinib (as sulfate) 20 mg/ml bottle

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate; hydroxypropylbetadex; purified water; sucralose; sodium benzoate; citric acid; flavour - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.